title: [Tuberculous prostatic abscess following intravesical bacillus Calmette-Guerin immunotherapy: a case report].
abstract: Intravesical bacillus Calmette-Guerin (BCG) was a common treatment for non-muscle invasive urothelial carcinoma of the bladder. The complication of prostatic abscess was rare. We reported a case of tuberculous prostatic abscess after BCG therapy. A 65-year-old man was diagnosed as bladder cancer and accepted transurethral resection of bladder tumor (TURBT) treatment. He received a 6-week induction course without any infection complication. Following the second BCG maintenance instillation, he complained of fever and dysuria. Transrectal ultrasound (TRUS) demonstrated a well-defined complex mass in the right lobe of his prostate. The diagnosis of tuberculous prostatic abscess was considered after excluding other bacterial infection. The patient was treated with an anti-tuberculous regimen of isoniazid, rifampicin, and ethambutol. The symptoms were relieved after 4 weeks of anti-tuberculous therapy. Because of the good response to the medicine, no further aspiration or drainage of prostatic abscess was carried out. The anti-tuberculous therapy had to be stopped for serious drug induced liver injury after 6 weeks of anti-tuberculous therapy. Eight weeks later of stopping anti-tuberculous therapy, the follow-up TRUS showed the disappearance of the prostatic abscess and the test of his liver function was normal. Considering the virulence of BCG is weaker than that of common tuberclebacillus, the shorter course of anti-tuberculous therapy maybe an alternative choice, and surgical drainage is not always necessary.
authors.affiliation: Department of Urology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Hai-yun
authors.initials: HY
authors.lastname: Ye
authors.affiliation: Department of Urology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Qing-quan
authors.initials: QQ
authors.lastname: Xu
authors.affiliation: Department of Urology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Xiao-bo
authors.initials: XB
authors.lastname: Huang
authors.affiliation: Department of Urology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Ma
authors.affiliation: Department of Urology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Wang
mesh_terms: D000038:Abscess / Q000139:chemically induced* / Q000175:diagnosis; D000283:Administration, Intravesical; D000368:Aged; D000970:Antineoplastic Agents; D001500:BCG Vaccine / Q000009:adverse effects*; D002278:Carcinoma in Situ; D004322:Drainage; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D008297:Male; D011469:Prostatic Diseases / Q000139:chemically induced* / Q000175:diagnosis; D014376:Tuberculosis / Q000175:diagnosis*; D001749:Urinary Bladder Neoplasms / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine